This study is looking at a new way to help surgeons see pancreatic cancer more clearly during surgery. It uses a drug called panitumumab-IRDye800, which combines an antibody drug (panitumumab) with a special dye (IRDye800CW) that can be seen with a special camera. The goal is to see if this combination makes cancer cells light up, making them easier to find and remove. You might be able to join if you have pancreatic adenocarcinoma, are planning to have surgery to remove the cancer, and are generally healthy enough for surgery. The main goal is to find the best dose of panitumumab-IRDye800 to make the tumor stand out from healthy tissue. This study is currently recruiting about 27 participants.

Study design

This is a Phase I/II interventional study that will enroll about 27 participants. It involves a dose-escalation phase to find the optimal dose.

What's involved

You would receive panitumumab and then panitumumab-IRDye800 intravenously (IV). Surgery would then take place 2-5 days later, involving special imaging during the procedure.

Compensation

Not stated in the trial record.

Follow-up

You will be followed up at 15 and 30 days after completing the study treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.